Detail
| LncRNA Name | XPLAID |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RNA-seq, qPCR etc. |
| Sample | prostate cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | The 43 differentially expressed (DE) lncRNAs between aggressive and indolent prostate cancers included 12 annotated and 31 novel lncRNAs. The top six DE lncRNAs were selected based on large, consistent fold-changes in the RNA-Seq results. Three of these candidates passed RT-qPCR validation, including AC009014.3 (P < .001 in tumor tissue) and a newly discovered X-linked lncRNA named XPLAID (P = .049 in tumor tissue and P = .048 in normal tissue). XPLAID and AC009014.3 show promise as prognostic biomarkers. SChLAP1 and XPLAID have elevated expression in both tumor and normal associated tissues of aggressive cancers, and AC009014.3 has elevated expression in tumors of indolent cancers. |
| Pubmed ID | 29723810 |
| Year | 2018 |
| Title | Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. |
| External Links |
| Links for XPLAID | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.